Enanta Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of common stock. The offering included a total of 7,475,000 shares.
This total includes 975,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares. The shares were sold to the public at a price of $10.00 per share.
The successful completion of this upsized offering provides Enanta with significant capital to fund its ongoing research and development programs. While strengthening the company's financial runway, the issuance of additional shares results in dilution for current shareholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.